1. Stocks
    2. /
  2. Eli Lilly (NYSE: LLY)
    3. /

Eli Lilly (NYSE: LLY) Share Price and News

$806.14 $-12.79 (-1.6%) Tuesday, 5 November 2024 at 8:00:00 am Australian Eastern Daylight Time

Eli Lilly Chart and Price Data

About Eli Lilly

Last updated 05-11-2024, 08:00:00am AEDT
Current Price $806.14
Change $-12.79 (-1.6%)
Close Price $806.14
Open Price $805.00
Bid $802.00
Ask $802.50
Day Range $803.68 - $820.19
Year Range $561.65 - $972.53
Volume 3,918,122
Average Volume 3,192,614
Market Cap $765,281,600,200.00
Earnings Per Share $9.14

    • Eli Lilly (NYSE: LLY)
    Latest News

    A man holds his head in his hands, despairing at the bad result he's reading on his computer.
    Healthcare Shares

    ResMed share price plunges 13% as weight-loss results reawaken worries

    | James Mickleboro

    Why are investors heading to the exits today? Let's see what's happening.

    Read more »

    A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
    Share Fallers

    Why Evolution Mining, Karoon Energy, ResMed, and Sayona Mining shares are dropping today

    | James Mickleboro

    These ASX shares are having a tough session. But why?

    Read more »

    A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
    Healthcare Shares

    Why is the ResMed share price diving 5% today?

    | James Mickleboro

    Weight loss wonder drugs are weighing heavily on this stock.

    Read more »

    A woman is excited as she reads the latest rumour on her phone.
    Broker Notes

    Goldman Sachs says this US stock is replacing Tesla in the Magnificent Seven

    | Bronwyn Allen

    And no, it's not a tech company. It's in the healthcare sector.

    Read more »

    medical asx share price represented by doctor giving thumbs up
    ETFs

    'Beyond our expectations': How to invest in obesity drugs like Ozempic with ASX ETFs

    | James Mickleboro

    This could be your way to invest in obesity drugs.

    Read more »

    Profile

    since

    Note